The in vitro antifungal activity of clotrimazole (Bay b 5097) was 
ml, respectively. One isolate of Allescheria boydii was resistant to 100 ,ig of amphotericin B per ml but was inhibited by 6.25 Aig of clotrimazole per ml. Clotrimazole was less active than amphotericin B against Candida albicans and Aspergillus fumigatus. The activity of clotrimazole against dermatophytes was comparable to that of pyrrolnitrin; 0.78 jig of either compound per ml was fungicidal for most isolates of Trichophyton sp., Microsporum sp. and Epidermophyton floccosum. Both griseofulvin and nystatin were less active than clotrimazole. The size of inoculum was shown to have a significant effect on the results of in vitro susceptibility testing with clotrimazole.
Clotrimazole, bis-phenyl-(2-chlorophenyl)-1-imidazolyl methane (Bay b 5097, Delbay Pharmaceuticals), is a chlorinated trityl imidazolyl with unique antifungal activity. Its in vitro spectrum includes yeasts, dermatophytes, dimorphic fungi, and dematiaceous species (4). Plempel et al. (4, 5) reported that it was inhibitory in vitro at concentrations of 4 ,ig or less per ml for most susceptible fungi and that many species, particularly Trichophyton and Candida, were inhibited by 1 ug/ml or less. However, it was said to be fungicidal only at concentrations greater than 20,ug/ml (4) .
Published data regarding the clinical effectiveness of clotrimazole are limited. In one report, it was described as being effective in one patient with a pulmonary aspergilloma, in another with bronchial infection due to Candida krusei, and in a third with tinea barbae due to C. albicans (3) . According to another report (2) The reported in vitro and in vivo activity of clotrimazole together with the initial clinical results stimulated much interest. A series of studies was initiated to define further the antifungal properties of this compound and to assess its potential in treatment of human mycotic disease. In the studies to be reported here, the in vitro activity of clotrimazole against systemic, dermatophytic, and opportunistic pathogenic fungi was compared with those of amphotericin B, griseofulvin, pyrrolnitrin, and nystatin.
MATERIALS DMSO. The concentrations of the dilution serials for amphotericin B, clotrimazole, nystatin, and pyrrolnitrin ranged from 200 to 0.10,g/ml; the range for griseofulvin was 100 to 0.05 ,ug/ml. The dilutions of drug in 2X-BHIB/,m were then mixed in equal volumes with modified, half-strength Sabhi agar and dispensed, after mixing, in 2.0-ml volumes. The concentrations of the drugs in the finished semisolid media ranged from 100 to 0.05 jig/ml for all drugs except griseofulvin for which they ranged from 50 to 0.025 ,g/ml.
Only amphotericin B and clotrimazole were tested in studies with yeastlike organisms. Stock solutions of the two drugs were first diluted in broth to a concentration of 100 ,g/ml and then serially diluted in broth. Final concentrations ranged from 100 to 0.05 ,ug/ml. The drug dilutions were dispensed in 2.0-ml volumes with three tubes per dilution for each test organism.
Tubes of semisolid medium were inoculated by dropping 0.03-to 0.05-ml volumes of the prepared inocula onto the surface of the hardened medium. Tubes containing liquid medium were inoculated by introducing 0.05-ml volumes of inoculum directly into the broth. Three tubes were inoculated per each dilution of drug or control for each organism. Controls included uninoculated sterility controls, drug and solvent-free growth controls, and growth controls containing 1.0% of the appropriate solvent.
Inoculated tubes were incubated at 30 C until growth appeared in the growth control tubes. The minimum time of incubation was 48 hr. After determination of the minimal inhibitory concentrations, 0.05-ml volumes of agar or of broth were transferred from all tubes showing no growth and from the first tubes in which growth was detectable to plates of Sabouraud agar. These were incubated at 30 C for 72 hr or until growth was apparent on those areas inoculated from tubes containing visible growth.
The following criteria were employed in recording and evaluating the results. When tubes were examined after the initial incubation period, they were scored as negative, partially inhibited, and positive. The lowest concentration of drug which produced complete inhibition in at least two of three tubes was regarded as the minimal inhibitory concentration (MIC). When the plates were examined after the second incubation period, they were scored as negative, three colonies or less, and positive. The lowest concentration of drug for which subcultures from at least two of three tubes were negative or grew no more than three distinct colonies was regarded as the minimal fungicidal concentration (MFC).
RESULTS
The in vitro activity of clotrimazole against yeastlike pathogens and mycelial phase cultures of the dimorphic systemic pathogens was generally comparable to that of amphotericin B (Table  1) . With the exception of the single isolate of A. boydii which was resistant to amphotericin B, all species were inhibited by both drugs. immitis were comparable, with 0.78 A.tg of either drug per ml being fungicidal for all but two isolates. These included the less susceptible isolate of H. capsulatum noted above and one isolate of C. immitis which was killed by amphotericin B at 1.56 ,g/ml and by clotrimazole at 0.78 Mg/inl.
None of the three strains of C. neoformans was killed by clotrimazole at concentrations less than 6.25 ,ug ml, whereas all three were killed by 0.78
Mg of amphotericin B per ml. Clotrimazole was both inhibitory and fungicidal for B. dermatitidis but at concentrations somewhat higher than those required for amphotericin B. Four of the five strains tested were inhibited by 0.78 ,ug of clotrimazole per ml, and the fifth was inhibited by 3.13 ,ug/ml. In contrast, four strains were inhibited by 0.20 ,g or less of amphotericin B per ml and the fifth by 0.39 ,Mg/ml. Three strains were killed by 1.56 ,ug or less of clotrimazole per ml, but the other two were not killed by less than 25 Mug/ml. In contrast, four strains were killed by 0.78 Mg of amphotericin B per ml and the fifth by 1.56 MAg/ml.
S. schenckii was somewhat more susceptible to clotrimazole than to amphotericin B. However, neither drug was inhibitory at concentrations less than 3.13 ,ug/ml nor fungicidal at concentrations less than 6.25 Mug/ml. Three strains were inhibited by clotrimazole at 3.13 Ag/ml and the other two at 6.25 ,ug/ml. Fungicidal activity was obtained at 6.25 jig/ml with three strains, at 12.5 ,g/ml with one strain, and at 25 ,g/ml with the fifth.
Amphotericin B was inhibitory for three strains at 6.25 and for two at 12.5 Mg/ml; fungicidal activity was measured against two strains at 12.5 ug/ml and three at 25 Mg/ml. During the course of these studies, a biopsy specimen from a case of maduromycosis was received for cultural studies. This specimen yielded an isolate of A. boydji for which susceptibility data were obtained for clotrimazole, amphotericin B, hamycin, and 5-fluorocytosine. Clotrimazole was the only one of the four drugs active against this isolate with inhibition at 6.25
,ug/ml but with no measurable fungicidal activity. Preliminary in vivo studies with this isolate have shown clotrimazole to be protective in infected mice treated orally with 100 mg/kg. S. cerevisiae was used as a control for testing with yeastlike fungi in these studies, and occasional fluctuations in inhibitory and fungicidal levels of clotrimazole for this organism were noted. These fluctuations were suspected to be due to variations in inoculum size. This was tested in one experiment in which inhibitory and fungicidal concentrations for S. cerevisae were determined by using a series of inocula of various densities. These were prepared by serial dilution of a dense suspension of S. cerevisiae with viable counts of each dilution being determined by a routine plate-counting procedure. The results clearly demonstrated a marked inoculum effect (Table 3) . With densities of 104 cells per ml or less, clotrimazole was inhibitory at a concentration of 0.05 ,g/ml and fungicidal at 0.20 to 6.25 ,g/ml. In contrast, at a density of 106 cells per ml, the drug was not inhibitory at less than 0.39 ,ug/ml nor fungicidal at less than 25 ,g/ml.
The antifungal activity of clotrimazole against 18 isolates of Trichophiyton species was compared with those of griseofulvin, pyrrolnitrin, and nystatin (Table 4 ). Clotrimazole and pyrrolnitrin were the most active with 0.39 ,ug of either per ml being fungicidal for most isolates. Griseofulvin and nystatin were less active against most isolates of Trichophyton. Only six isolates were susceptible to griseofulvin at concentrations less than 0.78 ug/ml, and three were resistant to concentrations greater than 3.13 ,g/ml.
The different species of Trichophyton varied in their susceptibility to the four compounds. T. tonsurans was less susceptible to clotrimazole than any of the other species, with two of these Falco, personal communication), whereas in an earlier study levels of 2.9 to 7 ,g/ml were reported in individuals receiving 20 mg/kg three times daily (4) .
The activity of clotrimazole against dermatophytes is comparable to that of pyrrolnitrin and superior to that of either nystatin or griseofulvin. More importantly, the ranges of inhibitory and fungicidal concentrations are narrow with little deviation either within or between species. In contrast, griseofulvin is inhibitory for T. rubrumn at 0.20 Mg ml but not for T. mentagrophytes at concentrations less than 3.13 Mg/mi. The data for griseofulvin are similar to those reported by Clotrimazole has certain desirable properties as an antifuingal agent. It is soluble in alcohols, stable to heat and moderate light, stable in alkaline solutions, quickly absorbed after oral administration and well distributed in tissues, devoid of toxicity in man at doses of 20 mg/kg three times daily, and active and well tolerated topically in animals. These properties combined with the broad spectrum of fungi affected suggest that it may be effective in treatment of human fungal disease. Such a suggestion, however, requires further clinical studies with this compound.
